옵션 체인은 다양한 행사가격과 만기일에 대한 Brookfield Infrastructure의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Brookfield Infrastructure에 대한 시장 심리를 평가합니다..

Brookfield Infrastructure (NYSE:BIPC) 주식, 옵션 체인

Brookfield Infrastructure

Brookfield Infrastructure Corp is an indirect subsidiary of the partnership of the diversified infrastructure owner and operators. Its business is comprised of a U.K. regulated distribution operation, a Brazilian regulated natural gas transmission operation and an international intermodal logistics operation. Geographically, the company generates a majority of its revenue from Brazil and rest from United Kingdom and the United States.

Ordinary Shares - Class A (Exchangeable Sub Voting)

Brookfield Infrastructure Corporation Brookfield Infrastructure Corporation

Brookfield Infrastructure Corp

News

Exclusives

MIRA

EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga 'Oral therapy designed to minimize CNS side effects shows dual activity in weight loss and smoking cessation models without muscle loss'

EXCLUSIVE: MIRA Pharmaceuticals Tells Benzinga Co. Reports Up To 30% Weight Loss And Reversal of High-Calorie And Nicotine Cravings In An Animal Model Of Obesity And Craving Using SKNY-1

MIRA Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) on Monday revealed new animal study results from SKNY-1, a next-generation oral therapeutic.
The company says the findings further support the advancement of SKNY-1 toward Investigational <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">New Drug (IND) enabling studies</a>.
With obesity and smoking representing two of the leading causes of preventable death and a combined global market opportunity exceeding $200 billion, MIRA intends to prioritize SKNY-1 as a potential cornerstone asset pending the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45281398/exclusive-mira-pharmaceuticals-board-approves-skny-pharma-acquisition-establishing-combined-enterprise-value-over-60-million" rel="noreferrer noopener">completion of the acquisition</a> of SKNY Pharmaceuticals, Inc.
In a zebrafish model that mimics human obesity and craving behaviors, SKNY-1 demonstrated weight loss, suppression of appetite and craving for high-calorie diets, and reversal of nicotine-seeking behavior—all achieved within six days of oral treatment.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45217506/exclusive-mira-pharmaceuticals-lead-program-ketamir-2-shows-no-brain-toxicity-in-fda-mandated-study" rel="noreferrer noopener">EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study</a>
SKNY-1 is being developed as an oral alternative to GLP-1 injectables, which are often limited by nausea, GI discomfort, injection reaction, and growing concerns around muscle loss.
<h2 class="wp-block-heading">Key Results</h2>
SKNY-1 reduced body weight by approximately 30% after six days of oral treatment. Treated animals weighed about 10% less than healthy controls. The company said the weight loss was not accompanied by muscle density changes.
Treated animals showed an increase in breathing rate, which is a reliable signal that their metabolism was speeding up.
In untreated obese animals, fat buildup in the liver was about 50% higher than normal. SKNY-1 reversed this buildup, bringing liver fat back to healthy levels. At the same time, cholesterol levels—including LDL (‘bad' cholesterol) and HDL (‘good' cholesterol)—also returned to normal without affecting fat levels in the blood.
Obese animals were eating 2–3 times more high-calorie food than normal. SKNY-1 dose-dependently reduced the behavior—high-dose animals ate less than healthy controls. The drug also made the animals less likely to pursue food in stressful environments and reduced obsessive food-seeking in tests designed to measure craving.
SKNY-1 significantly reduced the desire to seek out and consume nicotine. At the high dose, their behavior matched that of healthy animals with no nicotine craving.
Obese animals had extremely high levels of leptin (a hunger-regulating hormone) and unusually low levels of ghrelin (the ‘hunger signal'). SKNY-1 normalized both hormones, improving the body's ability to regulate hunger and energy use.
Obese animals had too much dopamine in their brains, likely tied to increased reward and cravings. SKNY-1 reduced these dopamine levels—but only at the lower dose. The high dose did not affect dopamine, suggesting the drug can reduce cravings without overstimulating the brain.
Price Action: MIRA stock is down 1.20% to $1.23 during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46163659/senate-republicans-propose-313-billion-cut-in-medicaid-spending-in-trumps-big-beautiful-bill" target="_blank" rel="noreferrer noopener">Senate Republicans Propose $313 Billion Cut In Medicaid Spending In Trump's ‘Big, Beautiful Bill'</a></li>
</ul>
Photo by shisu_ka via Shutterstock

Biotech

Health Care

Market-Moving Exclusives

General

EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study

Avadel Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit (the "Appeals Court") affirmed a prior decision of the U.S. District Court for the District of Columbia (the "District Court") in favor of the U.S. Food and Drug Administration ("FDA") in a suit brought by Jazz Pharmaceuticals Inc. ("Jazz") regarding the FDA's approval of LUMRYZTM, the first and only once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Following the District Court's ruling in favor of the FDA and Avadel in October 2024, which granted the FDA's Motions for Summary Judgment with respect to Jazz's complaint and denied Jazz's Motion for Summary Judgment, Jazz filed a notice of appeal to the Appeals Court. On June 27, 2025, the Appeals Court, in a unanimous panel decision, affirmed the District Court's ruling and upheld the FDA's approval of LUMRYZ.

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Appeals Court Upholds FDA Approval Of Avadel's LUMRYZ In Narcolepsy In Administrative Procedure Act Litigation

IONQ

Texas Legislature Passes IonQ-Backed Quantum Initiative, Paving The Way For Statewide Leadership In Quantum Innovation

Rep. Thomas Massie (R-Ky.) has warned that the passage of President Donald Trump's &#8216;One Big Beautiful Bill&#8217; could tank the U.S. credit rating to BBB status, a level that historically signals financial distress.
What Happened: In an X post, Massie quipped, "BBB = our credit rating if this bill becomes law," using the hashtag #sassywithmassie to underscore his skepticism.
The legislation, a sweeping tax and spending package, is set for a Senate vote, with the Congressional Budget Office projecting an increase in the national debt over the next decade.
Massie's critique comes amid growing concerns over fiscal responsibility, following a rare downgrade of U.S. debt to<a href="https://www.benzinga.com/news/econ-s/25/05/45479078/moodys-downgrades-us-credit-rating-over-debt-deficit-concerns"> Aa1 by Moody's</a> on May 16, which cited rising deficits and inadequate spending cuts.
The One Big Beautiful Bill, championed by President Trump, includes tax cuts on Social Security income and tips, alongside Medicaid restrictions, but critics like Massie argue it fails to address core conservative priorities like deficit reduction or welfare reform for illegal immigrants.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">"BBB" = our credit rating if this bill becomes law<a href="https://twitter.com/hashtag/sassywithmassie?src=hash&amp;ref_src=twsrc%5Etfw">#sassywithmassie</a>
&mdash; Thomas Massie (@RepThomasMassie) <a href="https://twitter.com/RepThomasMassie/status/1939128423093329955?ref_src=twsrc%5Etfw">June 29, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to a <a href="https://www.colorado.edu/today/2025/05/21/what-us-credit-downgrade-means-economy-and-your-wallet">report</a> by the University of Colorado, Nathalie Moyen, a finance professor at the Leeds School of Business, highlights that a credit downgrade could mean higher borrowing costs. Interest rates on loans, mortgages, and credit cards might rise as investors demand more return to offset perceived risk, directly hitting household budgets.
&#8220;Meanwhile, the U.S. government now faces higher interest payments on its own debt. Eventually, that pressure will likely lead to higher taxes or cuts in government spending, both of which will be felt by everyday Americans,&#8221; said Moyen.
Additionally, David Beahm, President &amp; CEO of Blanchard and Company, explained <a href="https://finance.yahoo.com/news/moody-us-credit-rating-downgrade-110454282.html">to</a> Yahoo Finance that the U.S. could be seen as a risky borrower after a downgrade, and &#8220;investors may demand higher interest rates in exchange for taking on what they see as greater risk in lending to the U.S.&#8221;
See Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46112471/ross-gerber-touts-an-idea-to-cut-deficit-by-trillions-of-dollars-let-the-tax-cuts-expire-and-full-salt-come-back">Ross Gerber Touts An Idea To Cut Deficit By Trillions Of Dollars: &#8216;Let The Tax Cuts Expire And Full SALT Come Back&#8217;</a>
Why It Matters: The Congressional Budget Office's estimates on the distributional impacts of the One Big Beautiful Bill Act revealed that tax adjustments, including the extension of 2017 tax act provisions, would<a href="https://www.benzinga.com/markets/equities/25/05/45536595/big-beautiful-bill-will-explode-the-deficit-and-make-the-rich-richer-congressional-budget-office-estimates-4-income-fall-for-lowest-decile-of-americans-by-2033"> drive a $3.8 trillion rise in the federal deficit</a>. 
Additionally, the CBO report highlights a $698 billion cut in federal subsidies due to modifications in the Medicaid program, alongside a $267 billion reduction in federal outlays for the Supplemental Nutrition Assistance Program (SNAP).
The report further noted, &#8220;Household resources would decrease by an amount equal to about 2 percent of income in the lowest decile (tenth) of the income distribution in 2027 and 4 percent in 2033, mainly as a result of losses of in-kind transfers, such as Medicaid and SNAP.&#8221;
Conversely, household resources would grow by 4% for those in the highest decile in 2027 and 2% in 2033, primarily due to &#8220;reductions in the taxes they owe.&#8221;
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were trading higher in premarket on Monday. The SPY was up 0.45% at $617.65, while the QQQ advanced 0.70% to $551.95, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
After hitting a fresh record on Friday, the futures of the S&amp;P 500, Nasdaq 100, and Dow Jones indices were trading higher on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/46068345/blackrock-bets-big-on-defense-companies-amid-escalating-geopolitical-tensions-palantir-lockheed-martin-northrop-grumman-among-stocks-in-focus" target="_blank" rel="noreferrer noopener">BlackRock Bets Big On Defense Companies Amid Escalating Geopolitical Tensions: Palantir, Lockheed Martin, Northrop Grumman Among Stocks In Focus</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Image Credit: CLIFFORD OTO/THE STOCKTON RECORD / USA TODAY NETWORK via Imagn Images

US Credit Rating Would Fall If Trump's Big Beautiful Bill Is Approved, Says Thomas Massie: Here's What It Means For Americans

<ul>
<li>Univation's new C3 AI–powered predictive maintenance solution for the petrochemical industry delivers enhanced operational efficiency, reduced maintenance expenses, and improved asset availability — leveraging insights from Dow Inc.'s successful implementation across its manufacturing facilities.</li>
<li>This collaboration builds off Dow's success with C3 AI Reliability, currently scaling across Dow's global steam cracking furnace fleet and other critical assets.</li>
</ul>

C3 AI And Univation Collaborate To Maximize Uptime And Cut Maintenance Costs For Petrochemical Manufacturers Worldwide

<ul>
<li>PanTracer Tissue evaluates over 500 cancer-related genes and aligns with clinical guidelines, covering key biomarkers recommended for therapy selection and additional genomic insights for clinical trial enrollment. Results may be delivered in as little as 8 days, enabling physicians to rapidly initiate treatment strategies. Minimal specimen requirements make it suitable for a wide range of tumor types and practice settings. The assay builds on the company's tissue-based CGP platform, previously known as NeoComprehensive Solid Tumor.</li>
<li>The addition of PanTracer Tissue + HRD offers enhanced tumor profiling by incorporating homologous recombination deficiency analysis into a single, guideline-aligned test for ovarian cancer. The PanTracer Tissue + HRD offering includes BRCA mutation status and a genomic instability score—critical biomarkers that can help guide the use of PARP inhibitors and other therapies targeting DNA repair pathways. The combined approach streamlines ordering and can shorten time to actionable results by capturing a broader range of clinically relevant genomic alterations, gene fusions, and DNA repair deficiencies.</li>
</ul>

NeoGenomics Announced The Launch Of PanTracer Tissue, A Next-generation Solid Tumor Profiling Assay, Including The Option To Add Testing For Homologous Recombination Deficiency

Nexstar Media Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXST#NASDAQ">NXST</a>) (the "Company") announced today that its wholly owned subsidiary, Nexstar Media Inc. ("Nexstar"), and Mission Broadcasting, Inc. ("Mission"), a variable interest entity of the Company, successfully completed refinancings of their revolving credit facilities, Term Loan A and Term Loan B in full. The refinancing extends maturities, provides expanded capacity under Nexstar's revolver, reduces interest rate margin and further strengthens the Company's capital structure and financial flexibility.
The new credit facilities include:
<ul>
<li>New $750 million Nexstar Revolving Credit Facility due 2030</li>
<li>New $75 million Mission Revolving Credit Facility due 2030</li>
<li>New $1,905 million Nexstar Term Loan A due 2030</li>
<li>New $1,300 million Nexstar Term Loan B due 2032</li>
</ul>
The revolving credit facilities and Term Loan A bear interest at the Secured Overnight Financing Rate (SOFR) plus 150 basis points per annum (subject to a pricing grid), representing a 10 basis point credit spread reduction compared to the rate on the prior credit facilities. The revolving credit facilities and Term Loan A priced with an upfront fee of 0.125% or 0.25% for rolled or new commitments. The Term Loan B bears interest at SOFR plus 250 basis points per annum, representing an 11 basis point credit spread reduction for 1-month SOFR compared to the rate on the prior Term Loan B. The Term Loan B priced with an original issue discount of 1.00%.
Together with cash on hand, the net proceeds of the new credit facilities refinanced Nexstar's $550 million revolving credit facility due 2027, Mission's $75 million revolving credit facility due 2027, Nexstar's $2,091 million Term Loan A due 2027 and Nexstar's $1,358 million Term Loan B due 2026 along with transaction fees and expenses.

NXST

Nexstar Media Subsidiaries Complete Refinancings Of Revolving Credit Facilities, Term Loan A And Term Loan B In Full; Refinancing Extends Revolving Credit Facility And Term Loan Maturities And Reduces Interest Rate Margin

INDV

Indivior Will Be Added As A Member Of The US Small-cap Russell 2000 Index, Effective After The Us Market Opens Today As Part Of The 2025 Russell Indexes Reconstitution.

Modine Unveils DSU Destratification Fan To Deliver Quiet, Energy-Efficient Airflow For Industrial And Commercial Facilities

<ul>
<li>Re-enters the mine on June 10th, consistent with previously provided timeline</li>
<li>Re-establishes ventilation, conducts a full inspection of the mine, restores hydraulic pressure along the longwall face, and confirms that key longwall components are in good condition</li>
<li>Decides to temporarily reseal the affected area of the mine on June 26th due to elevated carbon monoxide levels</li>
<li>Engages regulatory officials on a plan that is expected to facilitate the repositioning and restart of the longwall system within the next four months</li>
<li>Reiterates 2025 coking coal sales volume guidance for metallurgical segment despite delayed restart</li>
<li>Expects Leer South-related insurance recoveries in excess of $100 million&nbsp;</li>
</ul>

Core Natural Resources Temporarily Reseals Affected Leer South Mine Area Due To Carbon Monoxide Spike; Restart Targeted Within Four Months

<ul>
<li>Study highlights high mortality despite standard of care and provides critical data to optimize design for upcoming proof-of-concept trial for epetraborole</li>
<li>Observational Study funded by the National Institutes of Health</li>
</ul>

ANTX

AN2 Therapeutics Completed Its 200-patient Observational Study In Acute Melioidosis. The Study Evaluated Patients Receiving The Current Standard Of Care: IV Meropenem Or Ceftazidime

RP-A701 is a first-in-class gene therapy for the treatment of BAG3-associated dilated cardiomyopathy
BAG3-associated dilated cardiomyopathy is a rare, inherited heart condition caused by mutations in the BAG3 gene, leading to early-onset, progressive heart failure due to impaired cardiac function, high morbidity, and premature mortality
Rocket plans to conduct a Phase 1 trial in the U.S. and is working towards the first patient treatment
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Frocketpharma.com%2F&amp;esheet=54283361&amp;newsitemid=20250630555497&amp;lan=en-US&amp;anchor=Rocket+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=6a3f55fb2d18a5941dd91131e5832f93">Rocket Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Company's Investigational New Drug (IND) application for RP-A701, an AAVrh.74-based gene therapy candidate for the treatment of BAG3-associated Dilated Cardiomyopathy (BAG3-DCM), a severe form of heart failure characterized by progressive ventricular enlargement and impaired systolic function.

RCKT

Rocket Pharma Receives FDA Clearance For IND Application For RP-A701, Aavrh.74-Based Gene Therapy Candidate For Treatment Of BAG3-Associated Dilated Cardiomyopathy

LTRX

Lantronix Reaches Cooperation Agreement With Chain Of Lakes Investment Group, Appoints Jim Auker To Board

HC Wainwright &amp; Co. analyst Andrew Fein assumes Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) with a Buy rating and announces Price Target of $23.

Price Target

Initiation

Analyst Ratings

CADL

HC Wainwright & Co. Assumes Candel Therapeutics at Buy, Announces Price Target of $23

<ul>
<li>Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxylanthanum Carbonate (OLC).</li>
<li>No other concerns stated, including pre-clinical, clinical, or safety data.</li>
<li>The Company identified a second manufacturing vendor that has already produced OLC drug product, which could also be used to support the resolution of the Clinical Manufacturing and Controls (CMC) issues identified in the CRL.</li>
<li>The Company plans to immediately request a Type A meeting with the FDA to align on next steps.</li>
<li>Unicycive currently has an unaudited cash balance of approximately $20.7 million, with cash runway currently expected into the second half of 2026</li>
</ul>

UNCY

The FDA Issues Complete Response Letter For Unicycive Therapeutics' New Drug Application For Oxylanthanum Carbonate To Treat Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis

Walker & Dunlop Secures $170M To Refinance Post District, A Class A, Mixed-Use Complex Containing 580 Residential Units In Downtown Salt Lake City, Utah

Comments

Brookfield Infrastructure

Brookfield Infrastructure (BIPC) 옵션

Loading...

뉴스

파트너 / 기고자

벤징가 글로벌